Golimumab was effective in maintaining clinical improvement through year-5 ( ACR20 : 62.8-69 .9 % , DAS28-CRP : 75.2-84 .9 % for randomised patients ; PASI75 : 60.8-72 .2 % among randomised patients with 3 % body surface area involvement ) and inhibiting radiographic progression ( mean changes in PsA-modified SHS : 0.1-0 .3 ) among patients with radiographic data .